# Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

> **NCT03335774** · PHASE2 · COMPLETED · sponsor: **Nivagen Pharmaceuticals Inc.** · enrollment: 103 (actual)

## Conditions studied

- Internal Hemorrhoids

## Interventions

- **DRUG:** Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
- **DRUG:** Placebo (Vehicle) Suppository (Nivagen)

## Key facts

- **NCT ID:** NCT03335774
- **Lead sponsor:** Nivagen Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-03-05
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335774, "Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03335774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*